Is Midostaurin available globally?

Midostaurin, also known asMidostaurin, is an innovative multi-target kinase inhibitor that provides a new treatment option for newly diagnosed adult patients with acute myeloid leukemia (AML), especially those carrying specific gene mutations in FLT3. In the early stages of research on this drug, it was regarded as a potential broad-spectrum anti-tumor drug, showing activity against numerous solid tumors and hematopoietic tumors.

After in-depth research and development and clinical trials, midostaurin was officially approved on April 28, 2017. As an adjuvant chemotherapy drug, it has significantly improved the overall survival rate of AML patients. Not only that, but midostaurin also works well in treating certain rare blood disorders, such as systemic mastocytosis with mast cell leukemia, and other cancers that affect the blood, bone marrow, or lymphoid tissue.

The core ingredient of this drug isMidostaurin, a kinase inhibitor that can effectively inhibit a variety of enzymes that promote cell growth. Studies have confirmed that midostaurin can inhibit FLT3 receptor signaling and cell proliferation, and induce apoptosis in leukemia cells expressing ITD and TKD mutated FLT3 receptors, or overexpressing wild-type FLT3 and PDGF receptors. At the same time, it can also inhibit KIT signaling, cell proliferation and histamine release, and induce mast cell apoptosis.

For patients with AML associated withFTL3 mutations, the therapeutic effect of midostaurin has been clearly demonstrated. The drug's safety is widely recognized and its side effects are considered manageable in serious medical conditions. Midostaurin has also shown significant efficacy in the treatment of mast cell diseases. Although there have been no direct comparative studies with other treatments, the clinical benefits of midostaurin are particularly outstanding given the rarity of these diseases and the urgent medical needs of patients, and its side effects are acceptable.

Therefore, after evaluating the risks and benefits of midostaurin, many countries around the world have concluded that its benefits far outweigh the risks and have approved its marketing use. However, it is worth noting that as of September 2024, this original drug has not yet been sold in the Chinese market. We look forward to Chinese patients also benefiting from this innovative drug in the near future.